中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
7-氨基-4-氯甲基香豆素 | 7-amino-4-chloromethylcoumarin | 147963-22-2 | C10H8ClNO2 | 209.632 |
—— | 4-chloromethyl-7-phenylamino-2H-chromen-2-one | 1270046-64-4 | C16H12ClNO2 | 285.73 |
—— | 7-amino-4-(hydroxymethyl)-2H-1-benzopyran-2-one | 873950-21-1 | C10H9NO3 | 191.186 |
—— | 4-{[(7-amino-2-oxo-2H-1-benzopyran-4-yl)methyl]amino}butanoic acid | 873950-23-3 | C14H16N2O4 | 276.292 |
—— | 7-anilino-4-(1H-imidazol-1-ylmethyl)-2H-chromen-2-one | 1270046-30-4 | C19H15N3O2 | 317.347 |
Specific link between high fructose uptake and cancer development and progression highlighted fructose transporters as potential means to achieve GLUT-mediated discrimination between normal and cancer cells. The gained expression of fructose-specific transporter GLUT5 in various cancers offers a possibility for developing cancer-specific imaging and bioactive agents. Herein, we explore the feasibility of delivering a bioactive agent through cancer-relevant fructose-specific transporter GLUT5. We employed specific targeting of GLUT5 by 2,5-anhydro-D-mannitol and investigated several drug conjugates for their ability to induce cancer-specific cytotoxicity. The proof-of-concept analysis was carried out for conjugates of chlorambucil (CLB) in GLUT5-positive breast cancer cells and normal breast cells. The cytotoxicity of conjugates was assessed over 24 h and 48 h, and significant dependence between cancer-selectivity and conjugate size was observed. The differences were found to relate to the loss of GLUT5-mediated uptake upon increased conjugate size and hydrophobicity. The findings provide information on the substrate tolerance of GLUT5 and highlight the importance of maintaining appropriate hydrophilicity for GLUT-mediated delivery.